Covance Market Access - Asia-Pacific
Covance Market Access Services is an established leader in analysis, reimbursement and pricing of health care interventions.
Our Australian-based Market Access consultants form part of a global team based in Gaithersburg, San Diego, London, Singapore and Sydney. This commercially-focused group draws on more than 100 years of collective experience in health technology assessment including the preparation of over 300 submissions to the PBAC, PTAC, MSAC and other reimbursement agencies.
Explore our expertise below.
- Landscape reviews and market access assessments
- Reimbursement and pricing strategy development
- Clinician interviews, surveys, and advisory panels and stakeholder research
- Systematic and targeted literature reviews
- Reimbursement submissions for drugs, devices and other health care products focused on achieving commercial objectives
- Cost-effectiveness and cost-utility models
- Budget impact analyses and forecasts
- Cohort and individual patient simulations (e.g., Markov, discrete event, microsimulation)
- Dynamic models, including infectious diseases
- Bespoke software applications, including iPad tools
- Meta-analyses and meta-regressions
- Indirect treatment comparisons including Bucher method, Bayesian network analysis and specialised methods using individual patient data
- Customised trial data analysis
- Statistical data translation for economic models (e.g. survival extrapolations, utility estimation)
- Observational studies including chart reviews and registries
- Database analyses including Australian PBS 10% sample
- Treatment patterns
- Persistence and adherence
- Utilisation volumes by patient or prescriber characteristics
- Survival analysis
- Utility and willingness-to-pay studies
Beth O’Leary, Executive Director, BSc(Hons), MAACB, MPH, MSc (Strategy)
Beth O’Leary heads up the Sydney-based Market Access Services team. Beth’s areas of special expertise and interest include reimbursement strategy development, health outcomes research and health technology assessment. Beth has a wide range of consulting experience in health service projects, which includes applications to governments for reimbursement of pharmaceuticals and medical procedures involving new technology, market assessments, and health outcomes studies. Beth also lectured at postgraduate level at Edith Cowan University and has conducted seminars in Health Economics for healthcare professionals.
Prior to joining Covance, Beth held health economic roles with Quintiles and Wyeth Pharmaceuticals and was a lecturer in Clinical Biochemistry at Curtin University for eight years. Beth received her MPH and BSc (Hons) from the University of Western Australia.
Heather McElroy, Director, Health Economics BSc(Hons), MMedStat, AStat
Heather McElroy has 20 years of diverse experience as a statistician, including more than ten years working in medical research in the pharmaceutical industry, government, and academia. Her area of expertise includes the design and analysis of observational studies and randomised control trials, and the analysis of administrative datasets, such as data from Medicare, the Pharmaceutical Benefits Schemes, registries, and records from public hospitals and general practitioners.
Prior to joining Covance, Heather held statistical roles with Eli Lily Australia, Cancer Institute of NSW, University of Adelaide, Queen Elizabeth Hospital, and Medicare Australia. Heather received a BSc (Hons) degree in Mathematical Sciences from the University of Adelaide and a Masters of Medical Statistics from the University of Newcastle.
Adam Gordois, Director, Health Economics BA (Hons), MSc Health Econ
Adam has over 14 years of health economics consulting experience in Australia and the UK spanning the pharmaceutical and medical devices industries, Government and not-for-profit organizations. Areas of expertise include market access and reimbursement support, HTA and policy assessment, cost effectiveness modeling and forecasting. Adam has also published in and provided peer-reviews for a variety of health economics and clinical journals.
Prior to joining Covance, Adam was Director of Health Economics and Social Policy at Deloitte Access Economics in Sydney following senior health economics roles at IMS (Australia) and M-TAG, and a Research Fellow role at the York Health Economics Consortium, UK. Adam received a BA in Business Economics (Hons) from University of Leicester and an MSc in Health Economics (Distinction) from the University of York.
Sam Colman, Director, HEOR, BEc, BSc (Hons), MBiostat
Sam Colman has 17 years of experience as a statistician in government, academia, and industry, including 11 years in the pharmaceutical industry. He has expertise in several therapeutic areas including Oncology, Endocrine, Neuroscience, Cardiovascular Disease and Respiratory Disease. Sam has designed and analyzed a significant number of trial types including Parallel RCTs, Observational, Cross-Over, Case-Control, Sample Surveys, Meta-Analyses, and Chart Audits, and he has experience in all phases of clinical development (Phase I-Phase IV).
Sam has a strong health economics and outcomes research background with expertise in meta-analysis, indirect comparisons, and AUC estimates and has worked on a number of successful PBAC submissions in Australia. Sam received a BEc and a BSc (Honours, Statistics) from the Australian National University and a Masters of Biostatistics from the University of Sydney.